Aspirin for Prevention of Preeclampsia

Drugs

Volumn 77, Issue 17, 2017, Pages 1819-1831

  Atallah, A ^a,b   Lecarpentier, E ^c,d,e,f   Goffinet, F ^c,d,e,f   Doret Dion, M ^a,b   Gaucherand, P ^a,b   Tsatsaris, V ^c,d,e,f  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e PremUp Foundation   (France)

^f DHU Risques et Grossesse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN;

ARTICLE; CHRONOBIOLOGY; DRUG SYNTHESIS; DRUG USE; EARLY DIAGNOSIS; FEMALE; GESTATIONAL AGE; HISTORY OF MEDICINE; HUMAN; IATROGENIC DISEASE; NONHUMAN; PREECLAMPSIA; PREGNANCY; PRIMARY PREVENTION; PROPHYLAXIS; SECONDARY PREVENTION; INCIDENCE; RISK FACTOR;

ASPIRIN; FEMALE; HUMANS; INCIDENCE; PRE-ECLAMPSIA; PREGNANCY; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION;

EID: 85031925610     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0823-0     Document Type: Article

References (101)

1. Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800–6. doi:10.1056/NEJM200206063462309.
2. Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261. doi:10.3389/fimmu.2017.00261.
3. Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis. 2013;20:229–39. doi:10.1053/j.ackd.2013.01.014.
4. Bergel E, Carroli G, Althabe F. Ambulatory versus conventional methods for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev 2002:CD001231. doi:10.1002/14651858.CD001231.
5. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet. 2007;369:1791–8. doi:10.1016/S0140-6736(07)60712-0.
6. Woelkers D, Barton J, von Dadelszen P, Sibai B. The revised 2013 ACOG definitions of hypertensive disorders of pregnancy significantly increase the diagnostic prevalence of preeclampsia. Pregnancy Hypertens Int J Womens Cardiovasc Health. 2015;5:38. doi:10.1016/j.preghy.2014.10.075.
7. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7. doi:10.1053/j.semperi.2009.02.010.
8. von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16:1–14. doi:10.1007/s11906-014-0454-8.
9. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–33. doi:10.1016/S2214-109X(14)70227-X.
10. Lafont O. From the willow to aspirin. Rev Hist Pharm. 2007;55:209–16.
11. Botting RM. Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep PR. 2010;62:518–25.
12. West GB. Aspirin and the prostaglandins. Chem Drug. 1972;198:196–7.
13. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989;259:315.
14. Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, et al. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract. 2014;2014:382. doi:10.5339/gcsp.2014.53.
15. Maclouf J, Bellucci S. Role of prostaglandins and thromboxanes in cardiovascular physiopathology. Presse Medicale Paris Fr. 1983;1985(14):1603–6.
16. Bowen RS, Zhang Y, Gu Y, Lewis DF, Wang Y. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta. 2005;26:402–9. doi:10.1016/j.placenta.2004.07.007.
17. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693–7.
18. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol Baltim Md. 1950;2005(175):5423–9.
19. Chiang N, Serhan CN. Aspirin triggers formation of anti-inflammatory mediators: new mechanism for an old drug. Discov Med. 2004;4:470–5.
20. Takahashi Y. Molecular structure and regulation of cyclooxygenase. Nihon Rinsho Jpn J Clin Med. 1992;50:259–63.
21. Trnavský K, Zachar M. Correlation of serum aspirin esterase activity and half-life of salicylic acid. Agents Actions. 1975;5:549–52.
22. Bojić M, Sedgeman CA, Nagy LD, Guengerich FP. Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2015;73:49–56. doi:10.1016/j.ejps.2015.03.015.
23. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–84.
24. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10:453–8. doi:10.1016/S0165-6147(89)80010-0.
25. Das UN. COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit Int Med J Exp Clin Res. 2005;11:RA233–7.
26. Patrick J, Dillaha L, Armas D, Sessa WC. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–80. doi:10.1080/00325481.2015.1050341.
27. Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74:551–7.
28. Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release aspirin and prostaglandin inhibition. Lancet Lond Engl. 1986;1:1153–4.
29. Caron N, Rivard G-E, Michon N, Morin F, Pilon D, Moutquin J-M, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2009;31:1022–7.
30. Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther. 2002;40:135–41.
31. Basinski A, Naylor CD. Aspirin and fibrinolysis. Lancet Lond Engl. 1988;2:1188–9.
32. Chen Y-H, Lin S-J, Chen Y-L, Liu P-L, Chen J-W. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets. 2006;6:279–304.
33. Kim J, Lee K-S, Kim J-H, Lee D-K, Park M, Choi S, et al. Aspirin prevents TNF-α-induced endothelial cell dysfunction by regulating the NF-κB-dependent miR-155/eNOS pathway: role of a miR-155/eNOS axis in preeclampsia. Free Radic Biol Med. 2017;104:185–98. doi:10.1016/j.freeradbiomed.2017.01.010.
34. Doridot L, Passet B, Méhats C, Rigourd V, Barbaux S, Ducat A, et al. Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. Hypertens Dallas Tex. 1979;2013(61):662–8. doi:10.1161/HYPERTENSIONAHA.111.202994.
35. Erdemli HK, Yıldırımlar P, Alper TY, Kocabaş R, Salis O, Bedir A. Increased serum heme oxygenase-1 levels as a diagnostic marker of oxidative stress in preeclampsia. Hypertens Pregnancy. 2014;33:488–97. doi:10.3109/10641955.2014.946613.
36. Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30:260–79. doi:10.3109/07420528.2012.717455.
37. Bonten TN, Saris A, van Oostrom MJ, Snoep JD, Rosendaal FR, Zwaginga J, et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost. 2014;112:1209–18. doi:10.1160/TH14-05-0453.
38. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids. 2004;70:223–32.
39. Lecarpentier E, Haddad B, Goffinet F, Tsatsaris V. Moyens thérapeutiques de la prise en charge de la pré-éclampsie. Presse Médicale. 2016;. doi:10.1016/j.lpm.2016.04.017.
40. Mousa AA, Strauss JF, Walsh SW. Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. Hypertension. 2012;59:1249–55. doi:10.1161/hypertensionaha.111.188730.
41. Panagodage S, Yong HE, Da Silva Costa F, Borg AJ, Kalionis B, Brennecke SP, Murthi P. Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia. Am J Pathol. 2016;186(12):3217–24.
42. Scazzocchio E, Oros D, Diaz D, Ramirez JC, Ricart M, Meler E, et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11–14 weeks: a randomized controlled study. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2017;49:435–41. doi:10.1002/uog.17351.
43. Walsh SW. Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia. Am J Perinatol. 1989;6:124–32. doi:10.1055/s-2007-999562.
44. Perneby C, Vahter M, Åkesson A, Bremme K, Hjemdahl P. Thromboxane metabolite excretion during pregnancy – influence of preeclampsia and aspirin treatment. Thromb Res. 2011;127:605–6. doi:10.1016/j.thromres.2011.01.005.
45. Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36:446–53. doi:10.1016/j.placenta.2015.01.004.
46. Vieillefosse S, Guibourdenche J, Atallah A, Haddad B, Fournier T, Tsatsaris V, et al. Predictive and prognostic factors of preeclampsia: interest of PlGF and sFLT-1. J Gynecol Obstet Biol Reprod (Paris). 2016;45:999–1008. doi:10.1016/j.jgyn.2016.02.006.
47. Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003;88:5555–63. doi:10.1210/jc.2003-030528.
48. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Val Med J Quincy Ill. 1956;78:213–5.
49. Beaufils M, Donsimoni R, Uzan S, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. The Lancet. 1985;325:840–2. doi:10.1016/S0140-6736(85)92207-X.
50. Uzan S, Beaufils M, Breart G, Uzan S, Bazin B, Capitant C, et al. Originally published as Volume 1, Issue 8755Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. The Lancet. 1991;337:1427–31. doi:10.1016/0140-6736(91)93124-R.
51. Anonymous. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343(8898):619–29.
52. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338:701–5. doi:10.1056/NEJM199803123381101.
53. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322:329–33.
54. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. In: The Cochrane Collaboration (ed). Cochrane Database Syst. Rev. Wiley, Chichester; 2007.
55. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14. doi:10.1097/AOG.0b013e3181e9322a.
56. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216(121–128):e2. doi:10.1016/j.ajog.2016.10.016.
57. Henderson JT, Whitlock EP, O’Conner E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014.
58. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.
59. Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol. 2015;126:1242–50.
60. Sibai BM. Therapy: low-dose aspirin to reduce the risk of pre-eclampsia? Nat Rev Endocrinol. 2015;11:6–8. doi:10.1038/nrendo.2014.199.
61. MOUNIER-VEHIER C. Consensus d’Experts de la Société Française d’Hypertension Artérielle 2015. http://www.sfhta.eu/wp-content/uploads/2015/11/Recommandations_HTA_et_grossesse_dec_2015202.pdf. Accessed 19 June 2016.
62. Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695–703. doi:10.7326/M13-2844.
63. Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia: Updated Recommendations—ACOG n.d. http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations. Accessed 20 Apr 2017.
64. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary n.d. https://sogc.org/wp-content/uploads/2014/05/gui307CPG1405Erev.pdf.
65. Hypertension in pregnancy: diagnosis and management | Guidance and guidelines | NICE n.d. https://www.nice.org.uk/guidance/CG107. Accessed 20 Apr 2017.
66. Guidance regarding the use of low-dose aspirin in the prevention of pre-eclampsia in high-risk women. n.d. https://www.midwife.org.nz/.
67. Krieger VI, Weiden S. The value of the cold pressor test in the prediction of hypertension and toxaemia in pregnancy. Med J Aust. 1947;1:417–23.
68. Parra-Cordero M, Turan OM, Kaur A, Pearson JD, Nicolaides KH. Maternal serum soluble adhesion molecule levels at 11 + 0-13 + 6 weeks and subsequent development of pre-eclampsia. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2007;20:793–6. doi:10.1080/14767050701500349.
69. Caradeux J, Serra R, Nien J-K, Pérez-Sepulveda A, Schepeler M, Guerra F, et al. First trimester prediction of early onset preeclampsia using demographic, clinical, and sonographic data: a cohort study. Prenat Diagn. 2013;33:732–6. doi:10.1002/pd.4113.
70. Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013;208:203.e1–10. doi:10.1016/j.ajog.2012.12.016.
71. Odibo AO, Patel KR, Spitalnik A, Odibo L, Huettner P. Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes. J Perinatol Off J Calif Perinat Assoc. 2014;34:186–91. doi:10.1038/jp.2013.176.
72. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2013;41:538–44. doi:10.1002/uog.12264.
73. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30:742–9. doi:10.1002/uog.5157.
74. Villa PM, Kajantie E, Räikkönen K, Pesonen A-K, Hämäläinen E, Vainio M, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG Int J Obstet Gynaecol. 2013;120:64–74. doi:10.1111/j.1471-0528.2012.03493.x.
75. Poon LCY, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertens Dallas Tex. 1979;2009(53):812–8. doi:10.1161/HYPERTENSIONAHA.108.127977.
76. Oliveira N, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG, Baschat AA. External validity of first-trimester algorithms in the prediction of pre-eclampsia disease severity. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2014;44:286–92. doi:10.1002/uog.13433.
77. Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2014;44:279–85. doi:10.1002/uog.13435.
78. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214:103.e1–12. doi:10.1016/j.ajog.2015.08.034.
79. Rolnik D, Wright D, Poon L, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;. doi:10.1056/NEJMoa1704559.
80. Roberge S, Nicolaides KH, Desmers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(110–120):e6.
81. Tan M, Koutoulas L, Wright D, Nicolaides KH, Poon L. A study protocol for the prospective validation study: screening programme for pre-eclampsia (SPREE). Ultrasound Obstet Gynecol. 2017;. doi:10.1002/uog.17467.
82. Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco Matallana C, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2017;. doi:10.1002/uog.18816.
83. Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA. Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0175283. doi:10.1371/journal.pone.0175283.
84. Chen W-C, Lin K-H, Huang Y-T, Tsai T-J, Sun W-C, Chuah S-K, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 2017;. doi:10.1111/apt.14079.
85. Benito-Garcia E, Michaud K, Wolfe F. The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. J Rheumatol. 2007;34:1765–9.
86. Belcon MC, Rooney PJ, Tugwell P. Aspirin and gastrointestinal haemorrhage: a methodologic assessment. J Chronic Dis. 1985;38:101–11.
87. Stevenson DD, White AA, Simon RA. Aspirin as a cause of pancreatitis in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2012;129:1687–8. doi:10.1016/j.jaci.2012.04.016.
88. Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407–13. doi:10.2500/ajra.2016.30.4370.
89. Lei H, Gao Q, Liu S-R, Xu J. The benefit and safety of aspirin for primary prevention of ischemic stroke: a meta-analysis of randomized trials. Front Pharmacol. 2016;7:440. doi:10.3389/fphar.2016.00440.
90. Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics. 2003;111:e77–81. doi:10.1542/peds.111.1.e77.
91. Jacobson RL, Brewer A, Eis A, Siddiqi TA, Myatt L. Transfer of aspirin across the perfused human placental cotyledon. Am J Obstet Gynecol. 1991;165:939–44.
92. Hertz-Picciotto I, Hopenhayn-Rich C, Golub M, Hooper K. The risks and benefits of taking aspirin during pregnancy. Epidemiol Rev. 1990;12:108–48.
93. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet Lond Engl. 1976;1:1373–5.
94. Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology. 1988;37:249–55. doi:10.1002/tera.1420370310.
95. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med. 1989;321:1639–42. doi:10.1056/NEJM198912143212404.
96. Nørgård B, Puhó E, Czeizel AE, Skriver MV, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192:922–3. doi:10.1016/j.ajog.2004.10.598.
97. Sasidharan CK, Kutty PM, Ajithkumar, Sajith N. Fetal intracranial hemorrhage due to antenatal low dose aspirin intake. Indian J Pediatr. 2001;68(11):1071–2.
98. Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105:286–92.
99. Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171:892–900.
100. Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication? Z Geburtshilfe Neonatol. 2005;209:65–8. doi:10.1055/s-2005-864116.
101. Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2011;14:469–74. doi:10.2350/07-11-0368.1.